Nad (nicotinamide Adenine Dinucleotide) And Derivatives Thereof Patents (Class 536/26.24)
-
Patent number: 10975411Abstract: The present invention provides a method for measuring the concentration of an analyte in a test solution wherein the analyte is mevalonic acid and/or 3-hydroxymethylglutaryl coenzyme A, comprising the following steps (p) and (q): (p) a step of allowing an enzyme that catalyzes a reaction represented by Reaction Formula 1 and an enzyme that catalyzes a reaction represented by Reaction Formula 2 to act on a test solution containing mevalonic acid and/or 3-hydroxymethylglutaryl coenzyme A in the presence of a hydrogen acceptor X, a hydrogen donor Y, and coenzyme A; and (q) a step of measuring an amount of: a reduced hydrogen acceptor X that is produced; or an oxidized hydrogen donor Y that is produced; or a hydrogen acceptor X that is decreased; or a hydrogen donor Y that is decreased, wherein the hydrogen donor Y and the reduced hydrogen acceptor X are not the same.Type: GrantFiled: August 11, 2016Date of Patent: April 13, 2021Assignee: ASAHI KASEI PHARMA CORPORATIONInventor: Takeshi Matsuoka
-
Patent number: 8889125Abstract: The present invention relates to a method of treatment and/or ameliorating the symptoms of Huntington's disease comprising the step of administering an effective amount of adenosine triphosphate, co-carboxylase, nicotinamide, and cyanocobalamin in a physiologically acceptable carrier to an individual in need thereof. Preferably, the administration is via intramuscular injection.Type: GrantFiled: March 15, 2013Date of Patent: November 18, 2014Assignee: Genix Therapeutics Group, LLCInventor: Ragab El-Rashidy
-
Publication number: 20140256930Abstract: An object of the present invention is to provide a method for converting the coenzyme dependency of enzymes of the medium-chain dehydrogenase/reductase (MDR) family. A further object of the present invention is to provide enzyme variants of the MDR family whose coenzyme dependency is converted by the conversion method and a method for enzymatically producing optically active alcohols using the enzymes. The present inventors developed a novel enzyme conversion method for converting the coenzyme dependency of enzymes of the MDR family, rationally designed enzyme variants that are altered by the enzyme conversion method to be able to use NADPH as a coenzyme from a useful enzyme of the MDR family that uses NADH as a coenzyme, and actually provide variants having such an ability.Type: ApplicationFiled: June 27, 2012Publication date: September 11, 2014Applicant: KANEKA CORPORATIONInventors: Shinichi Yoshida, Shunichi Taira, Masakatsu Nishihachijyo, Masutoshi Nojiri, Shigeru Kawano
-
Publication number: 20140142291Abstract: The disclosure concerns the enzymatic synthesis of stable analogues of nicotinamide adenine dinucleotide NAD/NADH and nicotinamide adenine dinucleotide phosphate NADP/NADPH, the so-called “carba-NADs”, i.e. analogues of NAD/NADH or NADP/NADPH, respectively, comprising a carbacyclic sugar instead of ribose.Type: ApplicationFiled: October 3, 2013Publication date: May 22, 2014Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.Inventors: Hartmut Duefel, Dieter Heindl, Carina Horn, Thomas Meier, Rainer Schmuck
-
Publication number: 20140045798Abstract: The present invention provides a compound of Formula Ia, wherein R1 is H or phosphate and the double bond is between N1 and C1 or between N2 and C1; R2 is a mitochondrial targeting moiety; R3 an alkyl, alkylaryl, alkylheteroaryl spacer group, a cleavable linker, or absent; R4 is H or an alkyl, aryl, or heteroaryl group; and R5 is alkyl, aryl, or heteroaryl; or N1 C1, and N3 together form a heterocyclic ring containing at least 5 atoms, wherein N1, N3, and R1-R5 are as defined above, or N3 and R5 together form a heterocyclic ring containing at least four atoms; or a pharmaceutically acceptable salt or prodrug thereof.Type: ApplicationFiled: October 18, 2013Publication date: February 13, 2014Applicant: Gencia CorporationInventor: Shaharyar Khan
-
Publication number: 20130072462Abstract: The present invention provides a compound of Formula 1a, wherein R1 is H or phosphate and the double bond is between N? and C? or between N2 and C1; R2 is a mitochondrial targeting moiety; R3 an alkyl, alkylaryl, alkylheteroaryl spacer group, a cleavable linker, or absent; R4 is H or an alkyl, aryl, or heteroaryl group; and R5 is alkyl, aryl, or heteroaryl; or N? C?, and N3 together form a heterocyclic ring containing at least 5 atoms, wherein N1, N3, and R1-R5 are as defined above, or N3 and R5 together form a heterocyclic ring containing at least four atoms; or a pharmaceutically acceptable salt or prodrug thereof.Type: ApplicationFiled: August 17, 2012Publication date: March 21, 2013Applicant: Gencia CorporationInventor: Shaharyar Khan
-
Publication number: 20130011871Abstract: In one non-limiting aspect, sterilizable reagent materials for diagnostic elements are provided. In other aspects, sterilized diagnostic elements and techniques for the production of the same are disclosed. In one embodiment, a sterilized diagnostic element includes a chemical detection reagent including at least one component that is sensitive to ionizing radiation. The sterilized diagnostic element is also mediator-free and the at least one component sensitive to ionizing radiation is present in a functional form in a proportion of ? 80% based on the total amount of the respective component in the diagnostic element before sterilization. In certain aspects, the at least one component sensitive to ionizing radiation includes one or both of an enzyme and a coenzyme. Other aspects include, but are not limited to, unique methods, techniques, products, systems and devices involving sterilizable reagent materials or sterilized diagnostic elements.Type: ApplicationFiled: June 11, 2012Publication date: January 10, 2013Inventors: Carina Horn, Nelli Steinke
-
Publication number: 20120130062Abstract: The disclosure concerns the enzymatic synthesis of stable analogues of nicotinamide adenine dinucleotide NAD/NADH and nicotinamide adenine dinucleotide phosphate NADP/NADPH, the so-called “carba-NADs”, i.e. analogues of NAD/NADH or NADP/NADPH, respectively, comprising a carbacyclic sugar instead of ribose.Type: ApplicationFiled: January 25, 2012Publication date: May 24, 2012Applicant: Roche Diagnostics Operations, Inc.Inventors: Hartmut Duefel, Dieter Heindl, Carina Horn, Thomas Meier, Rainer Schmuck
-
Patent number: 8133872Abstract: The administration of nicotinic acid adenine dinucleotide phosphate (NAADP) or a pharmaceutically acceptable salt thereof to a host in need thereof for the treatment of type-2 diabetes has been disclosed.Type: GrantFiled: May 19, 2009Date of Patent: March 13, 2012Assignee: Industrial Cooperation Foundation, Chonbuk National UniversityInventors: Uh Hyun Kim, Kwang Hyun Park, Myung Kwan Han
-
Patent number: 8003324Abstract: The present invention relates to the use of oxidized nicotinamide adenine dinucleotide (NAD+) or of its reduced form, NADH, as sodium channel modulators. The present invention also relates to the use of compositions containing NAD+ or NADH to treat conditions associated with sodium channel current, such as arrhythmia. NAD+ is found to increase sodium channel current, while NADH is found to decrease sodium channel current. Thus, conditions that are associated with decreased sodium channel current can be treated with NAD+, while conditions that is associated with increased sodium channel current can be treated with NADH.Type: GrantFiled: October 17, 2008Date of Patent: August 23, 2011Assignees: U.S. Department of Veterans Affairs, Emory UniversityInventor: Samuel C. Dudley, Jr.
-
Publication number: 20110177316Abstract: The invention relates to a method for producing a biodegradable molded part, comprising: providing a binding agent which contains a lyzable biopolymer; forming a molded part from the binding agent, wherein the time stability of the molded part to biological lysis is set by at least one of the following measures: adding a pulverized inorganic solid matter in a proportion of 5% to 85% of the mass of the binding agent before forming the molded part; thawing at least one of the surfaces of the molded part using a chemical or biological method such that the surface has a structuring in the range between 1 nm and 10 ?m. The invention further relates to an accordingly produced molded part.Type: ApplicationFiled: October 3, 2008Publication date: July 21, 2011Applicant: LEONARDIS-STIFTUNGInventors: Klaus Rennebeck, Bernd Hildenbrand
-
Patent number: 7553615Abstract: The invention concerns stable nicotinamide adenine dinucleotide (NAD/NADH) and nicotinamide adenine dinucleotide phosphate (NADP/NADPH) derivatives, enzyme complexes of these derivatives and their use in biochemical detection methods and reagent matrices.Type: GrantFiled: July 27, 2006Date of Patent: June 30, 2009Assignee: Roche Diagnostics Operations, Inc.Inventors: Dieter Heindl, Joachim Hoenes, Carina Horn, Piet Herdewijn
-
Patent number: 7521432Abstract: Novel compositions and methods are provided for identifying agents which affect chromosomal stability and aging.Type: GrantFiled: April 25, 2007Date of Patent: April 21, 2009Assignee: Wisconsin Alumni Research FoundationInventors: John M. Denu, Kirk G. Tanner
-
Patent number: 7396658Abstract: The present invention relates to rapid, quantitative, specific, high through-put methods for screening test substances for their ability to inhibit activity of an ouabain-resistant Na+—K+-ATPase involved in a variety of biological processes such as regulation of osmotic balance and cell volume, maintenance of the resting membrane potential, establishment of the ionic composition of cerebrospinal fluid and aqueous humor, electrical activity of muscle and nerve, and receptor-mediated endocytosis, cardiac muscle contractility, neurotransmitter metabolism and vascular muscle cell contraction. These methods can be employed to identify compounds for use in therapeutic applications for disease processes in which dysfunction of the Na+—K+-ATPase contributes to a pathological process. The present invention also includes kits which are used in the methods provided herein.Type: GrantFiled: March 16, 2004Date of Patent: July 8, 2008Assignee: The General Hospital CorporationInventor: Garner T. Haupert, Jr.
-
Patent number: 7291606Abstract: Novel compositions and methods are provided for identifying agents which affect chromosomal stability and aging.Type: GrantFiled: November 13, 2001Date of Patent: November 6, 2007Assignee: Wisconson Alumni Research FoundationInventors: John M. Denu, Kirk G. Tanner
-
Patent number: 7056894Abstract: The present invention provides compounds having the formula: wherein A is chosen from a nitrogen-, oxygen-, or sulfur-linked aryl, alkyl, cyclic, or heterocyclic group; both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen; and D is a primary alcohol, a hydrogen, or an oxygen, nitrogen, carbon, or sulfur linked to phosphate, a phosphoryl group, a pyrophosphoryl group, or adenosine monophosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted phosphodiester bridge, or to adenosine diphosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted pyrophosphodiester bridge. The present invention also provides pharmaceutical compositions containing the above compounds, methods of using the above compounds as pharmaceuticals, and processes for preparing the above compounds.Type: GrantFiled: January 4, 2002Date of Patent: June 6, 2006Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Anthony A. Sauve, Vern L. Schramm
-
Patent number: 7034011Abstract: It is an object of the present invention to provide a method of stabilizing reduced nicotinamide adenine dinucleotide or reduced nicotinamide adenine dinucleotide phosphate [hereinafter abbreviated as NAD(P)H] and a preparation containing NAD(P)H stabilized by the method. As the method of stabilizing NAD(P)H, a method of adding astaxanthin to NAD(P)H is provided.Type: GrantFiled: December 3, 2003Date of Patent: April 25, 2006Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Hideo Kawabe, Hideki Murata, Hiroshi Nagano
-
Patent number: 7022680Abstract: The present invention provides compounds having the formula: wherein A is a nitrogen-, oxygen-, or sulfur-linked aryl, alkyl, cyclic, or heterocyclic group, the group being further substituted with an electron contributing moiety; B is hydrogen, or a halogen, amino, or thiol group; C is hydrogen, or a halogen, amino, or thiol group; and D is a primary alcohol, a hydrogen, or an oxygen, nitrogen, carbon, or sulfur linked to phosphate, a phosphoryl group, a pyrophosphoryl group, or adenosine monophosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted phosphodiester bridge, or to adenosine diphosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted pyrophosphodiester bridge. The present invention also provides pharmaceutical compositions containing the above compounds, methods of using the above compounds as pharmaceuticals, and processes for preparing the above compounds.Type: GrantFiled: May 30, 2002Date of Patent: April 4, 2006Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Anthony A. Sauvé, Vern L. Schramm
-
Patent number: 6846646Abstract: The present invention relates to rapid, quantitative, specific, high through-put methods for screening test substances for their ability to inhibit activity of an ouabain-resistant Na+-K+-ATPase involved in a variety of biological processes such as regulation of osmotic balance and cell volume, maintenance of the resting membrane potential, establishment of the ionic composition of cerebrospinal fluid and aqueous humor, electrical activity of muscle and nerve, and receptor-mediated endocytosis, cardiac muscle contractility, neurotransmitter metabolism and vascular muscle cell contraction. These methods can be employed to identify compounds for use in therapeutic applications for disease processes in which dysfunction of the Na+-K+-ATPase contributes to a pathological process. The present invention also includes kits which are used in the methods provided herein.Type: GrantFiled: December 24, 1998Date of Patent: January 25, 2005Assignee: The General Hospital CorporationInventor: Garner T. Haupert, Jr.
-
Patent number: 6713623Abstract: Disclosed are novel bicyclic tris(anhydride)s useful as intermediates in the synthesis of biologically active compounds, and the compounds which may be synthesized from such intermediates.Type: GrantFiled: November 13, 2001Date of Patent: March 30, 2004Assignee: Pharmasset, Ltd.Inventors: Krzysztof W. Pankiewicz, Krystyna Lesiak, Kyoichi A. Watanabe
-
Patent number: 6689760Abstract: This invention provides compositions of matter, pharmaceutical compounds, methods of synthesizing such compounds and methods for using such compounds to treat animals infected with a pathogenic mycobacterium. The invention specifically provides compositions and pharmaceutical compositions thereof for the treatment of tuberculosis and other Mycobacterium-caused diseases.Type: GrantFiled: July 10, 2000Date of Patent: February 10, 2004Assignee: EnzRel Inc.Inventors: Milton B. Yatvin, Richard L. Pederson
-
Publication number: 20030022266Abstract: Novel agents acting as co-factors for replacement of NAD(P)+/NAD(P)H co-enzyme systems in enzymatic oxido-reductive reactions. Agents mimicking the action of NAD(P)+/NAD(P)H system in enzymatic oxidation/reduction of substrates into reduced or oxidized products. A method for selection and preparation of the mimicking agents for replacement of NAD(P)+/NAD(P)H system and a device comprising co-factors for replacement of NAD(P)+/NAD(P)H system.Type: ApplicationFiled: March 12, 2001Publication date: January 30, 2003Inventors: Richard H. Fish, John B. Kerr, Christine H. Lo
-
Patent number: 6344201Abstract: “Black holes” in the genomes of bacterial pathogens represent deletions of “anti-virulence” genes, i.e. genes that are detrimental to a pathogenic lifestyle. Identification of the missing genetic loci in the “black hole” identifies genes that are incompatible with the bacteria's pathogenicity. These genes, their gene products, and compounds generated by the enzymatic action of these gene products represent potential new compounds that are inhibitory to the bacterial pathogen and thus useful as pharmaceuticals. The utility of this concept is demonstrated in the missing gene for lysine decarboxylase, and the resulting inhibitory activity of cadaverine (the diaminoalkyl reaction product of lysine decarboxylase) on the Shigella enterotoxins. Diaminoalkyl compounds are therefore potent inhibitors of E. coli and Shigella spp. enterotoxins. Lysine decarboxylase generated from the gene cadA results in attenuation of the enterotoxic effects.Type: GrantFiled: March 30, 1999Date of Patent: February 5, 2002Inventors: Anthony T. Maurelli, Reinaldo E. Fernández, Craig A. Bloch, Alessio Fasano
-
Patent number: 6339073Abstract: This invention provides a method of killing tumor cells or microorganisms which comprises contacting the tumor cells or the microorganisms with an amount of nicotinamide adenine dinucleotide (NAD) or its analogs effective to increase clonogenic toxicity of cells. This invention also provides a method of killing tumor cells or microoganisms in a subject which comprises administering an amount of nicotinamide adenine dinucleotide or its analogs effective to increase clonogenic toxicity of cells to the subject.Type: GrantFiled: September 9, 1998Date of Patent: January 15, 2002Assignee: Oxigene, Inc.Inventor: Ronald W. Pero
-
Patent number: 6326490Abstract: Disclosed are novel bicyclic tris(anhydride)s useful as intermediates in the synthesis of biolologically active compounds, and the compounds which may be synthesized from such intermediates.Type: GrantFiled: October 10, 1997Date of Patent: December 4, 2001Assignee: Pharmasset, Ltd.Inventors: Krzysztof W. Pankiewicz, Krystyna Lesiak, Kyoichi A. Watanabe
-
Patent number: 6207649Abstract: The invention relates to pharmaceutical compositions of nucleoside dimers containing an L-sugar in at least one of the nucleosides.Type: GrantFiled: December 23, 1998Date of Patent: March 27, 2001Assignee: Lipitek International, Inc.Inventors: Alexander L Weis, Kirupathevy Pulenthiran
-
Patent number: 5211289Abstract: There is provided a new and useful removable lid, particularly adapted for commercial sized containers of the type which holds oils, grease, bulk food stuffs and the like. The lid comprises a central lid area which has parallel upper and lower surfaces. A continuous channel extends about the periphery of the lower surface. The channel has inner and outer walls for releasably receiving therebetween the upper lid of a container. A skirt downwardly depends about the periphery of the lid area. The skirt forms part of the outer wall of the channel. Means at the bottom of the channel act as a seal between the lid and the container when the lid is in position on the container.Type: GrantFiled: May 27, 1992Date of Patent: May 18, 1993Assignee: Irving Oil LimitedInventor: Walter A. Matthews